K Number
K242411
Manufacturer
Date Cleared
2025-02-19

(189 days)

Product Code
Regulation Number
892.1750
Reference & Predicate Devices
Predicate For
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The e-Lung software provides reproducible CT values for pulmonary tissue, which is essential for providing quantitative support in the examination of radiological findings. These radiological findings can then be evaluated by the physician in conjunction with a range of ancillary information to form a potential diagnosis or list of likely diagnoses. The e-Lung software package is intended to be a workflow enhancement and visualization tool for the assessment of CT thoracic datasets. e-Lung can be used to support the physician when examining the pulmonary and thoracic tissue (i.e. lung parenchyma) in CT thoracic datasets. 3D segmentation, volumetric measurements, density evaluations, and reporting tools are combined with a dedicated workflow.

Device Description

Brainomix 360 e-Lung is a software package compliant with the DICOM standard and running on an off-the-shelf physical or virtual server. e-Lung is a CT processing module which operates within the integrated Brainomix 360 platform.

Brainomix 360 e-Lung is a stand-alone software device which uses a set of image processing algorithms to perform evaluation (3D segmentation and isolation of sub-compartments, volumetric measurements, and density evaluations), editing, and reporting tools which are combined with a dedicated workflow.

e-Lung can be used to support the physician in the documentation of radiological findings that may be indicative of chest diseases when examining the pulmonary and thoracic tissue (i.e. lung parenchyma) in CT thoracic datasets. These radiological findings are then evaluated in conjunction with a range of ancillary information to form a potential diagnosis or list of likely diagnoses.

e-Lung is designed to analyze pulmonary CT slice data and display analysis results. Each voxel of the scan is measured by Hounsfield units (HU), a measurement of x-ray attenuation that is applied to each volume element in three-dimensional space. The HU are utilized to distinguish between air, water, tissue and bone, such distinction is common in the industry.

e-Lung provides computed tomography (CT) viewing, and parenchymal density analysis in one application. e-Lung provides quantitative measurements and tabulates quantitative properties.

e-Lung focuses on what is visible to the eye and applies volumetric methods that might otherwise be too time consuming to use.

The software does not perform any function which cannot be accomplished by a trained user utilizing manual tracing methods; the software does not reconstruct a 3D rendering image of the lung; the intent of the software is to enhance the workflow by saving time and automating potential error prone manual tasks.

e-Lung has functions for loading, and saving datasets, and will generate screen displays, computations and aggregate statistics. e-Lung data output may be exported to a CSV, Excel or PDF file.

AI/ML Overview

Here's a summary of the acceptance criteria and study details for the Brainomix 360 e-Lung device, based on the provided text:

Acceptance Criteria and Device Performance

The device's performance was evaluated based on the accuracy of its lung segmentation algorithm compared to a predicate device.

Acceptance CriteriaReported Device Performance
Lung segmentation accuracy (Quantitative)The Dice Similarity Coefficient (DSC) values for the AI/ML segmentation algorithm (proposed device) were significantly higher than the segmentation method of the predicate device (V=11628, p<0.0001). The histogram in Figure 1 shows the AI/ML algorithm having a higher concentration of DSC values around 0.99, while the predicate device has a broader distribution with a peak around 0.97.
Device generalizabilityThe AI/ML segmentation algorithm works effectively across all patient types, demonstrating no impact by changes to the algorithm across a range of clinically relevant parameters, including demographics, clinical variables (BMI, smoking status, radiological findings) and scanner or image variables (location, scanner manufacturer, slice thickness, KvP and reconstruction method).

Study Details

  1. Sample size used for the test set and the data provenance: The document does not explicitly state the numerical sample size for the test set, but it implies a cohort of lung images used for the Dice Similarity Coefficient comparison. The provenance of the data (country of origin, retrospective/prospective) is not specified.

  2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Ground truth for the test set was established by the consensus of three experienced US board-certified radiologists.

  3. Adjudication method for the test set: Ground truth was established by the consensus of the three radiologists. This implies a method where all three radiologists agreed, or a majority rule was applied for cases of disagreement, though the specific process is not further detailed.

  4. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: A multi-reader multi-case (MRMC) comparative effectiveness study focusing on how human readers improve with AI vs. without AI assistance was not explicitly mentioned. The study described is a head-to-head comparison of the AI/ML algorithm (proposed device) against a predicate device algorithm, not a comparison of human reader performance with and without AI assistance.

  5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Yes, the study clearly describes a standalone performance evaluation of the AI/ML segmentation algorithm. It was a "head-to-head comparison" between the proposed device's algorithm and the predicate device's algorithm for lung mask generation, compared against a ground truth.

  6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.): The ground truth used was expert consensus from three experienced US board-certified radiologists who segmented the lungs following their usual standard of care.

  7. The sample size for the training set: The sample size for the training set is not specified in the provided document.

  8. How the ground truth for the training set was established: The document does not specify how the ground truth for the training set was established. It only details the ground truth establishment for the test set used in the validation study.

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

February 19, 2025

Brainomix Limited % Zsolt Szrnka Regulatory Affairs Manager First Floor, Seacourt Tower West Way OXFORD. OX2 0JJ UNITED KINGDOM

Re: K242411

Trade/Device Name: Brainomix 360 e-Lung Regulation Number: 21 CFR 892.1750 Regulation Name: Computed Tomography X-Ray System Regulatory Class: Class II Product Code: JAK Dated: August 14, 2024 Received: January 16, 2025

Dear Zsolt Szrnka:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatory

{2}------------------------------------------------

assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Lu Jiang

Lu Jiang, Ph.D. Assistant Director Diagnostic X-ray Systems Team DHT8B: Division of Radiologic Imaging Devices and Electronic Products OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

Indications for Use

Submission Number (if known)

K242411

Device Name

Brainomix 360 e-Lung

Indications for Use (Describe)

The e-Lung software provides reproducible CT values for pulmonary tissue, which is essential for providing quantitative support in the examination of radiological findings. These radiological findings can then be evaluated by the physician in conjunction with a range of ancillary information to form a potential diagnosis or list of likely diagnoses. The e-Lung software package is intended to be a workflow enhancement and visualization tool for the assessment of CT thoracic datasets. e-Lung can be used to support the physician when examining the pulmonary and thoracic tissue (i.e. lung parenchyma) in CT thoracic datasets. 3D segmentation, volumetric measurements, density evaluations, and reporting tools are combined with a dedicated workflow.

Type of Use (Select one or both, as applicable)

X Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

K242411

Image /page/4/Picture/1 description: The image shows the logo for BRAINOMIX. The logo consists of a stylized brain icon on the left, followed by the word "BRAINOMIX" in a sans-serif font. The brain icon is a gradient of blue and teal, while the word "BRAINOMIX" is mostly gray, with the "AI" portion in a matching blue and teal gradient.

510(k) Summary Brainomix Limited – Brainomix 360 e-Lung

Date Prepared:16Jan2025
Applicant's Name:Brainomix Limited
Applicant's Address:First Floor, Seacourt Tower, West WayOxford, OX 0JJUnited Kingdom
Official Contact:Zsolt Szrnka+44 (0) 1865 582730regulatory@brainomix.com
Device Proprietary Name:Brainomix 360 e-Lung
Device Classification Name:System, X-Ray, Tomography, Computed
Regulatory Class:Class II
Product Code:JAK
Regulation Number:21 C.F.R. §892.1750
Regulation Name:Computed tomography x-ray system

1. Predicate Device

Brainomix 360 e-Lung is Substantially Equivalent to the following Legally Marketed device:

Trade Name: Brainomix 360 e-Lung Manufacturer: Brainomix Ltd. Regulation Number: 21 C.F.R. §892.1750 Regulatory Class: Class II Regulation Name: Computed tomography x-ray system Product Code: JAK Submission Number: K233875

2. Device Description

Brainomix 360 e-Lung is a software package compliant with the DICOM standard and running on an off-the-shelf physical or virtual server. e-Lung is a CT processing module which operates within the integrated Brainomix 360 platform.

Brainomix 360 e-Lung is a stand-alone software device which uses a set of image processing algorithms to perform evaluation (3D segmentation and isolation of sub-compartments, volumetric measurements, and density evaluations), editing, and reporting tools which are combined with a dedicated workflow.

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the logo for BRAINOMIX. The logo consists of a stylized brain icon on the left, followed by the word "BRAINOMIX" in bold, sans-serif font. The brain icon and the "AI" in the word "BRAINOMIX" are in a gradient of light blue to teal, while the rest of the word is in dark gray.

e-Lung can be used to support the physician in the documentation of radiological findings that may be indicative of chest diseases when examining the pulmonary and thoracic tissue (i.e. lung parenchyma) in CT thoracic datasets. These radiological findings are then evaluated in conjunction with a range of ancillary information to form a potential diagnosis or list of likely diagnoses.

e-Lung is designed to analyze pulmonary CT slice data and display analysis results. Each voxel of the scan is measured by Hounsfield units (HU), a measurement of x-ray attenuation that is applied to each volume element in three-dimensional space. The HU are utilized to distinguish between air, water, tissue and bone, such distinction is common in the industry.

e-Lung provides computed tomography (CT) viewing, and parenchymal density analysis in one application. e-Lung provides quantitative measurements and tabulates quantitative properties.

e-Lung focuses on what is visible to the eye and applies volumetric methods that might otherwise be too time consuming to use.

The software does not perform any function which cannot be accomplished by a trained user utilizing manual tracing methods; the software does not reconstruct a 3D rendering image of the lung; the intent of the software is to enhance the workflow by saving time and automating potential error prone manual tasks.

e-Lung has functions for loading, and saving datasets, and will generate screen displays, computations and aggregate statistics. e-Lung data output may be exported to a CSV, Excel or PDF file.

3. Intended Use / Indications for Use

The e-Lung software provides reproducible CT values for pulmonary tissue, which is essential for providing quantitative support in the examination of radiological findings. These radiological findings can then be evaluated by the physician in conjunction with a range of ancillary information to form a potential diagnosis or list of likely diagnoses. The e-Lung software package is intended to be a workflow enhancement and visualization tool for the assessment of CT thoracic datasets. e-Lung can be used to support the physician when examining the pulmonary and thoracic tissue (i.e. lung parenchyma) in CT thoracic datasets. 3D segmentation, volumetric measurements, density evaluations, and reporting tools are combined with a dedicated workflow.

4. Performance Data

e-Lung complies with DICOM (Digital Imaging and Communications in Medicine) – developed by the American College of Radiology and the National electrical Manufacturers Association. NEMA PS 3.1 – 3.20.

The lung segmentation performance of the updated algorithm was validated through a head-to-head comparison between proposed and predicate devices. The study evaluated the accuracy of the e-Lung lung mask generation compared to a ground truth mask generated from the consensus of three experienced US board certified radiologists, who segmented the lungs following their usual standard of care. It was demonstrated that the Dice Similarity Coefficient (DSC) values were significantly higher

{6}------------------------------------------------

Image /page/6/Picture/0 description: The image shows the logo for Brainomix. The logo consists of a stylized brain icon on the left, followed by the word "BRAINOMIX" in a sans-serif font. The brain icon is a gradient of blue and green, while the letters "AI" in the word "BRAINOMIX" are also in the same gradient of blue and green, while the rest of the letters are in a dark gray color.

for the AI/ML segmentation algorithm method (proposed device) than the segmentation method of the predicate device (V=11628, p<0.0001) (see Figure 1). Furthermore, the clinical study also entailed a secondary objective, which was to demonstrate that device generalizability across a range of clinically relevant parameters, including demographics, clinical variables (BMI, smoking status, radiological findings) and scanner or image variables (location, scanner manufacturer, slice thickness, KvP and reconstruction method) was not impacted by the changes to the algorithm. It was concluded that the proposed device's Al/ML segmentation algorithm works effectively across all patient types.

Image /page/6/Figure/3 description: The image is a histogram comparing the Dice Similarity Coefficient of two segmentation methods, CNN and Predicate. The x-axis represents the Dice Similarity Coefficient, ranging from 0.95 to 0.99, while the y-axis represents the count. The histogram shows the distribution of Dice Similarity Coefficients for each method, with CNN having a higher concentration of values around 0.99 and Predicate having a broader distribution with a peak around 0.97.

Figure 1. Histogram showing the distribution of Dice Similarity Coefficients (DSC) for the lung images segmented using the AI/ML segmentation algorithm (pink) vs the predicate segmentation algorithm (blue).

The longitudinal assessment feature and outputs to PACS and cloud were thoroughly verified as part of the software verification and validation activities. Software performance, validation and verification testing demonstrated that e-Lung met all design requirements and specifications.

5. Prescriptive Statement

Caution: Federal law restricts this device to sale by or on the order of a physician.

6. Safety and Effectiveness

Brainomix 360 e-Lung has been designed, verified and validated in compliance with 21 CFR, Part 820.30 requirements. The device has been designed to meet the requirements associated with ISO 14971:2019 (risk management).

{7}------------------------------------------------

Image /page/7/Picture/0 description: The image shows the logo for BRAINOMIX. The logo consists of a stylized brain icon on the left, followed by the word "BRAINOMIX" in a bold, sans-serif font. The brain icon is a gradient of light blue to dark blue, and the "AI" in "BRAINOMIX" is also in the same gradient of blue, while the rest of the letters are in dark gray.

7. Cybersecurity

Brainomix 360 e-Lung has been designed to follow the FDA Cybersecurity Guidance and IEC 81001-5-1.

8. Summary of Technological Characteristics

Brainomix 360 e-Lung principal workflow for chest CT datasets includes the following key steps:

  • Chest CT images loading. Brainomix 360 e-Lung provides an automated workflow which will । : automatically process image data received by the system.
    1. lmage processing function. Brainomix 360 e-lung processes chest CT scans and first generates a lung mask followed by any structural density filters or density histogram filters that have been pre-configured by an admin user.
    1. Generation of summary results report
    1. Image and results viewing. This is a non-diagnostic DICOM application allowing a trained clinician to view the CT image and associated results within the web UI. Results can also be sent and reviewed in PACS. The user is then able to edit the periphery of the lungs for that case and view updated quantifications. If multiple scans are available for a patient, images and results can be viewed simultaneously. These results may then be evaluated in conjunction with a range of ancillary information as part of the patient pathway.

Brainomix 360 e-Lung includes similar chest CT processing features and technological characteristics as compared to the predicate device. The intended use and principles of operation of the subject device are the same as those of the predicate device. There are no changes to the predicate e-Lung implementation that change the previously cleared features. Significant differences between the subject and predicate e-Lung devices are as follows:

  • . Improved algorithm for lung segmentation (AI/ML algorithm)
  • . Automated grouping of scans that have had the same workflow applied and calculation of differences in density evaluations between CTs (longitudinal assessment feature)
  • . Outputs in PACS and Cloud

Furthermore, minor improvements were also carried out with the aim of increasing the user's comfort when interacting with the device by providing additional PACS/DICOM viewing functionalities of adjustable slab thickness reconstructions, ability to view scans at original resolution and dynamic MPR with cross hair. Minor changes also include improvements in the visualization of outputs, additional user-defined options in relation to the structural density filters and improvement to the radiologist workflow by enabling networking and linking cases.

9. Clinical Characteristics

Brainomix 360 e-Lung can be used to support the physician when examining the pulmonary and thoracic tissue by providing quantifications of radiographic features through density evaluations and volumetric measurements including lung volume derived from a segmentation of the lungs.

{8}------------------------------------------------

Image /page/8/Picture/0 description: The image shows the logo for BRAINOMIX. The logo consists of a stylized brain icon on the left, followed by the word "BRAINOMIX" in a sans-serif font. The brain icon is a gradient of blue and green, while the letters "AI" in the word "BRAINOMIX" are also in a similar gradient.

Quantification of these features provides additional objective and reproducible data which can be used by physicians in addition to the current standard of care to aid diagnosis and longitudinal assessment of lung disease.

Substantial Equivalence 10.

A table comparing the key features of the proposed and predicate device is provided below.

Characteristics/ParameterProposed DeviceBrainomix 360 e-LungPredicate DeviceBrainomix 360 e-LungComparison
510(k) NumberK242411K233875N/A
Product CodeJAKJAKIdentical
RegulationNumber21 CFR §892.175021 CFR §892.1750Identical
Regulation NameSystem, X-Ray, Tomography,ComputedSystem, X-Ray, Tomography,ComputedIdentical
IntendedUse/Indicationsfor UseThe e-Lung software providesreproducible CT values forpulmonary tissue, which isessential for providingquantitative support in theexamination of radiologicalfindings. These radiologicalfindings can then be evaluated bythe physician in conjunction with arange of ancillary information toform a potential diagnosis or listof likely diagnoses. The e-Lungsoftware package is intended tobe a workflow enhancement andvisualization tool for theassessment of CT thoracicdatasets. e-Lung can be used tosupport the physician whenexamining the pulmonary andthoracic tissue (i.e. lungparenchyma) in CT thoracicdatasets. 3D segmentation,volumetric measurements, densityevaluations, and reporting toolsare combined with a dedicatedworkflow.The e-Lung software providesreproducible CT values forpulmonary tissue, which isessential for providingquantitative support in theexamination of radiologicalfindings. These radiologicalfindings can then be evaluated bythe physician in conjunction with arange of ancillary information toform a potential diagnosis or listof likely diagnoses. The e-Lungsoftware package is intended tobe a workflow enhancement andvisualization tool for theassessment of CT thoracicdatasets. e-Lung can be used tosupport the physician whenexamining the pulmonary andthoracic tissue (i.e. lungparenchyma) in CT thoracicdatasets. 3D segmentation,volumetric measurements, densityevaluations, and reporting toolsare combined with a dedicatedworkflow.Identical
Image SourceModalitiesCTCTIdentical
DICOMConformanceYesYesIdentical
Interface OutputWeb UI, PACS and cloudWeb UIDifferent
ComparativeReview2D2DIdentical
3D Lung MappingNoNoIdentical
Characteristics/ParameterProposed DeviceBrainomix 360 e-LungPredicate DeviceBrainomix 360 e-LungComparison
3DMeasurements3D volume of masks3D volume of masksIdentical
2DMeasurementsNoneNoneIdentical
DensityMeasurementsAdmin user defined densityhistogram evaluation andstructural density filteringevaluationAdmin user defined densityhistogram evaluation andstructural density filteringevaluationIdentical
DeploymentStandard off-the-shelf server orvirtual serverStandard off-the-shelf server orvirtual serverIdentical
OSUbuntu LinuxUbuntu LinuxIdentical
User InterfaceYesYesIdentical
AlgorithmEach voxel of the scan is measuredby Hounsfield Units (HU), ameasurement of x-ray attenuationthat is applied to each volumeelement in three-dimensionalspace ('voxel'). The HU are utilizedto distinguish between air, water,tissue and bone, such distinction iscommon in the industry.An AI/ML image processingapproach is applied to CT imagingdata to automatically segmentlung mask.Each voxel of the scan is measuredby Hounsfield Units (HU), ameasurement of x-ray attenuationthat is applied to each volumeelement in three-dimensionalspace ('voxel'). The HU are utilizedto distinguish between air, water,tissue and bone, such distinction iscommon in the industry.A (non-AI) image processingapproach is applied to CT imagingdata to automatically segmentlung mask.Similar, bothdevicessegment alung mask,however,theproposeddeviceutilizes anAI/MLalgorithm toperform thistask
WorkflowAutomated segmentationAutomated measurements(including those based on userconfigurations)Automated grouping of scansfrom the same patient andautomated measurementsAutomated segmentationAutomated measurements(including those based on userconfigurations)Similar,addedlongitudinalassessmentfeature(grouping ofscans fromthe samepatient)
Graphic UserInterfaceYesYesIdentical
Interactive 3DVisualizationNoNoIdentical
Input/OutputUsers can browse, select, and loadCT scan files. Users can save andload analyses, export via reportingtools. CT scan files are organizedby patient in the scan viewer. Usercan generate a report thatdisplays quantitative data itemsthat can be saved. DICOM infodisplayed. Data import throughDICOM query/retrieve available.Users can browse, select, and loadCT scan files. Users can save andload analyses, export via reportingtools. CT scan files are organizedby patient in the scan viewer. Usercan generate a report thatdisplays quantitative data itemsthat can be saved. DICOM infodisplayed. Data import throughDICOM query/retrieve available.Identical
Path PlanningNoNoIdentical
User EditingYesYesIdentical
ReportsYes – CSV, Excel and PDF formatYes – CSV, Excel and PDF formatIdentical
Characteristics/ParameterProposed DeviceBrainomix 360 e-LungPredicate DeviceBrainomix 360 e-LungComparison
Scan QualityAssessmentScan protocol is assessed forcompatibility with software Incompatibility issues flaggedduring import and on reportScan protocol is assessed forcompatibility with software Incompatibility issues flaggedduring import and on reportIdentical

{9}------------------------------------------------

Image /page/9/Picture/0 description: The image shows the logo for BRAINOMIX. The logo consists of a stylized brain icon on the left, followed by the word "BRAINOMIX" in a sans-serif font. The brain icon is split into two halves, with a gradient of blue and green. The word "BRAINOMIX" is in a dark gray color, with the "A" in "BRAINOMIX" having a blue gradient.

Head office

First Floor, Seacourt Tower, West Way Oxford OX2 0JJ, United Kingdom

{10}------------------------------------------------

Image /page/10/Picture/0 description: The image shows the logo for BRAINOMIX. The logo consists of a teal-colored graphic on the left, resembling a brain. To the right of the graphic is the word "BRAINOMIX" in a sans-serif font, with the "AI" in a gradient of teal to blue.

First Floor, Seacourt Tower, West Way Oxford OX2 0JJ, United Kingdom

Table 1. Comparison of the key features of the subject and predicate device.

11. Conclusion

Brainomix 360 e-Lung includes similar chest CT processing features and technological characteristics as compared to the predicate device. The intended use and principles of operation of the subject device are the same as those of the predicate device. The differences in technological characteristics for the proposed device do not raise different questions of safety or effectiveness.

The proposed device does not raise different questions of safety and demonstrates substantial equivalence to the predicate, Brainomix 360 e-Lung (K233875).

§ 892.1750 Computed tomography x-ray system.

(a)
Identification. A computed tomography x-ray system is a diagnostic x-ray system intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from the same axial plane taken at different angles. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.